Paclitaxel or Nab-Paclitaxel

Phase 3Small molecule

Paclitaxel or Nab-Paclitaxel is one of 46 small molecule programs targeting Selected Advanced Solid Tumors. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Selected Advanced Solid TumorsActive, not recruiting

Non-Small Cell Lung CancerNot yet recruiting

Selected Advanced Solid TumorsPhase 1

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Not yet recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Navelbine

PPierre Fabre Medicament

Phase 3

24 2

Oleclumab

AstraZeneca

Phase 3

7 3

Pyrotinib

HHengrui Therapeutics, Inc.

Phase 3

3 4

Paclitaxel or Nab-Paclitaxel

AstraZeneca

Phase 3

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Selected Advanced Solid Tumors

NCT03530397

Q1 2031

Phase 2/3Not yet recruiting

Non-Small Cell Lung Cancer

NCT07318883

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

Not yet recruiting· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Phase 2/3·NCT07318883·720 enrolled

Selected Advanced Solid Tumors1 trial

A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors.

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT03530397·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Paclitaxel or Nab-Paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Paclitaxel or Nab-Paclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Paclitaxel or Nab-Paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

Paclitaxel or Nab-Paclitaxel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2031

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Selected Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News